Cure8 research brief
This study describes how often people newly diagnosed with IBD go on biologic or JAK inhibitor therapy and what happened to them over five years — including hospital visits and surgery — which helps set expectations for newly diagnosed patients and their clinicians.
Newly diagnosed adult IBD patients (Crohn's disease or ulcerative colitis), their caregivers, gastroenterologists, and researchers studying treatment trajectories and outcomes.
This multicentre prospective cohort followed 3,301 adults with newly diagnosed IBD (2017 cohort in Spain) for 5 years and reports rates of biologic/JAK inhibitor use (30%), hospitalisation (34%), and abdominal surgery (9%). Use of biologics/JAKi was higher in Crohn's disease and linked with younger age, more aggressive CD phenotype, and greater UC extent.
Biologic/JAKi treatment was associated with lower hospitalisation risk for both CD and UC, but it did not reduce abdominal surgery risk overall and was associated with increased surgery risk in UC in this cohort. The report is grounded in the article abstract provided on PubMed (structured-content depth: abstract).
Numbers and associations above reflect the authors' analyses as summarized in the abstract; Cure8 did not review the full manuscript beyond the extracted abstract.
This is a prospective observational registry from Spain enrolling patients in 2017 and following them five years; associations (for example between biologic/JAKi use and surgery or hospitalisation) do not prove causation and may reflect treatment selection for more severe disease. The source content used here is the article abstract on PubMed.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study tests a new mechanism (TL1A inhibition) that may reduce inflammation and fibrosis in IBD. Positive phase 2b results suggest duvakitug could become another treatment option if later trials confirm benefit and...
The study suggests that a simple, multidomain functional measure (intrinsic capacity) is linked to later IBD risk and that combining it with genetic risk may better identify people at higher risk—especially for Crohn’s...
Patients, families, and clinicians may care because the study shows pediatric-onset IBD is more often Crohn's and that children begin advanced therapies earlier than adults. The adult persistence data for vedolizumab and...
